Timothy S. Pardee, MD

home / authors / timothy-s-pardee-md

Articles

Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AML

July 9th 2014

Timothy S. Pardee, MD, discusses comorbidities, age, and outcomes among intensively treated patients with acute myeloid leukemia (AML).

A Phase I Study of the Mitochondrial Metabolism Inhibitor CPI-613 for AML

Timothy S. Pardee, MD

June 23rd 2014

Timothy S. Pardee, MD, discusses the results of a phase I study of the mitochondrial metabolism inhibitor CPI-613 for relapsed or refractory acute myeloid leukemia (AML).

Initial Results from the CALGB 10801 Study

Timothy S. Pardee, MD

May 14th 2014

Timothy S. Pardee, MD, Assistant Professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, describes initial results of the CALGB 10801 (Alliance) study, which added dasatinib to standard induction and consolidation therapy for newly diagnosed patients with core binding factor (CBF) acute myeloid leukemia (AML).

The Mechanism and Utility of CPI-613 for the Treatment of Hematologic Malignancies

Timothy S. Pardee, MD

February 6th 2014

Timothy S. Pardee, MD, from Wake Forest University Baptist Medical Center, discusses the mechanism and utility of the pyruvate dehydrogenase complex inhibitor CPI-613 for the treatment of patients with advanced hematologic malignancies.